Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study
Background/Aim. The gold standard in treating the advanced ovarian cancer (AOC) is primary debulking surgery (PDS) followed by platinum-based adjuvant chemotherapy. In the AOC, the extent of tumor resection (residual tumor volume) is the most important prognostic factor for overall survival (OS) and...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2021-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84502000038M.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849703684682809344 |
|---|---|
| author | Maričić Slobodan Mandić Aljoša Dejanović Ninoslav Kladar Nebojša Popović Marina Ivković-Kapicl Tatjana Gutić Bojana Kokanov Dunja |
| author_facet | Maričić Slobodan Mandić Aljoša Dejanović Ninoslav Kladar Nebojša Popović Marina Ivković-Kapicl Tatjana Gutić Bojana Kokanov Dunja |
| author_sort | Maričić Slobodan |
| collection | DOAJ |
| description | Background/Aim. The gold standard in treating the advanced ovarian cancer (AOC) is primary debulking surgery (PDS) followed by platinum-based adjuvant chemotherapy. In the AOC, the extent of tumor resection (residual tumor volume) is the most important prognostic factor for overall survival (OS) and progression-free survival (PFS). Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is an experimental treatment of the AOC, introduced in clinical practice in order to improve cytoreduction rate and prolong survival. The aim of this study was to compare the survival and cytoreduction rate of NACT+IDS and PDS in patients with the AOC. Methods. This retrospective cohort study included patients with the AOC, separated into two groups. The first group treated with PDS had 59 patients, while the second group, treated with NACT + IDS, had 33 patients. Results. A lower rate of suboptimal cytoreduction (39.39%) was found in the NACT + IDS group than in the PDS group (57.63%). The percentage of complete cytoreduction was higher in patients treated with NACT + IDS (51.52%) than in those treated with PDS (38.98%). Nevertheless, median OS and PFS were not significantly different between the groups (p < 0.05). OS was 35 months and 31 months in the PDS and NACT + IDS groups, respectively. PFS was 16 months in the PDS and 19 months in the NACT + IDS group. Conclusion. Despite the higher rate of optimal debulking surgery after NACT+ IDS, survival of patients treated with method was not better than those treated with PDS. The decision for either NACT+IDS or PDS should be tailored to the individual patient. |
| format | Article |
| id | doaj-art-11a657e983c649b6b6b85e9fd0780bdc |
| institution | DOAJ |
| issn | 0042-8450 2406-0720 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-11a657e983c649b6b6b85e9fd0780bdc2025-08-20T03:17:09ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502406-07202021-01-0178111193119910.2298/VSP190110038M0042-84502000038MNeoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort studyMaričić Slobodan0Mandić Aljoša1https://orcid.org/0000-0002-6719-8694Dejanović Ninoslav2Kladar Nebojša3Popović Marina4Ivković-Kapicl Tatjana5Gutić Bojana6Kokanov Dunja7University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Sremska Kamenica, SerbiaUniversity of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Sremska Kamenica, SerbiaOncology Institute of Vojvodina, Sremska Kamenica, SerbiaUniversity of Novi Sad, Faculty of Medicine, Novi Sad, Serbia Oncology Institute of Vojvodina, Sremska Kamenica, SerbiaUniversity of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Sremska Kamenica, SerbiaUniversity of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Sremska Kamenica, SerbiaOncology Institute of Vojvodina, Sremska Kamenica, SerbiaBackground/Aim. The gold standard in treating the advanced ovarian cancer (AOC) is primary debulking surgery (PDS) followed by platinum-based adjuvant chemotherapy. In the AOC, the extent of tumor resection (residual tumor volume) is the most important prognostic factor for overall survival (OS) and progression-free survival (PFS). Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is an experimental treatment of the AOC, introduced in clinical practice in order to improve cytoreduction rate and prolong survival. The aim of this study was to compare the survival and cytoreduction rate of NACT+IDS and PDS in patients with the AOC. Methods. This retrospective cohort study included patients with the AOC, separated into two groups. The first group treated with PDS had 59 patients, while the second group, treated with NACT + IDS, had 33 patients. Results. A lower rate of suboptimal cytoreduction (39.39%) was found in the NACT + IDS group than in the PDS group (57.63%). The percentage of complete cytoreduction was higher in patients treated with NACT + IDS (51.52%) than in those treated with PDS (38.98%). Nevertheless, median OS and PFS were not significantly different between the groups (p < 0.05). OS was 35 months and 31 months in the PDS and NACT + IDS groups, respectively. PFS was 16 months in the PDS and 19 months in the NACT + IDS group. Conclusion. Despite the higher rate of optimal debulking surgery after NACT+ IDS, survival of patients treated with method was not better than those treated with PDS. The decision for either NACT+IDS or PDS should be tailored to the individual patient.http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84502000038M.pdfcytoreduction surgical proceduresdrug therapygynecologic surgical proceduresovarian neoplasmssurvivalprognosis |
| spellingShingle | Maričić Slobodan Mandić Aljoša Dejanović Ninoslav Kladar Nebojša Popović Marina Ivković-Kapicl Tatjana Gutić Bojana Kokanov Dunja Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study Vojnosanitetski Pregled cytoreduction surgical procedures drug therapy gynecologic surgical procedures ovarian neoplasms survival prognosis |
| title | Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study |
| title_full | Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study |
| title_fullStr | Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study |
| title_full_unstemmed | Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study |
| title_short | Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study |
| title_sort | neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer a retrospective cohort study |
| topic | cytoreduction surgical procedures drug therapy gynecologic surgical procedures ovarian neoplasms survival prognosis |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84502000038M.pdf |
| work_keys_str_mv | AT maricicslobodan neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy AT mandicaljosa neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy AT dejanovicninoslav neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy AT kladarnebojsa neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy AT popovicmarina neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy AT ivkovickapicltatjana neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy AT guticbojana neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy AT kokanovdunja neoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryversusprimarydebulkingsurgeryintheadvancedepithelialovariancanceraretrospectivecohortstudy |